News
-
-
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare as Sanofi transfers a 50% stake in Opella. Opella to become a standalone leader backed by Sanofi's strategic support and guidance -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: FRIEDRICH VORWERK grows by 32% in the third quarter to €145m in revenues with an EBITDA margin of 17.5% and raises its 2024 forecast to €430-460m in revenues with an EBITDA margin of 14-15 %
FRIEDRICH VORWERK reports 32% revenue growth in Q3, reaching €145m with EBITDA margin of 17.5%. Raises 2024 forecast to €430-460m revenues with 14-15% EBITDA margin -
COMMUNIQUÉ DE PRESSE
Volume growth rebounds, targeting full year organic growth at the lower end of the guidance, mid-term EBITDA margin target on track
ARYZTA AG reports volume growth rebound with full year organic growth target at lower end of guidance. Mid-term EBITDA margin target remains on track -
COMMUNIQUÉ DE PRESSE
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics receives Notice of Allowance for European Patent covering RLF-TD011 for Epidermolysis Bullosa wound treatment. The patent will protect RLF-TD011 until 2040 in key European countries, with applications under review in other major markets -
COMMUNIQUÉ RÉGLEMENTÉ
ICADE - CP - Activité au 30 septembre 2024
-
-
COMMUNIQUÉ DE PRESSE
HBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial year
HBM Healthcare Investments AG releases Half-Year Report, showing a profit of CHF 23 million with positive NAV and share price growth. Private and public companies both contribute to earnings -
COMMUNIQUÉ DE PRESSE
HBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial year
HBM Healthcare Investments reports CHF 23 million profit and 1.5% NAV increase for the first six months ending September 2024, despite 5% negative currency impact
